MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy

Trial Profile

MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MAIN-A
  • Most Recent Events

    • 16 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 16 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 06 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top